Form 4: Biodesix Executive Sells Shares to Cover Taxes After RSU Vesting
SEC Form 4
Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., sold shares of common stock to cover taxes upon the vesting of restricted stock units (RSUs).
Summary
- On February 10, 2025, Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., exercised restricted stock units (RSUs) converting them into 45,729 shares of common stock.
- On February 11, 2025, Pestano sold 16,748 shares of Biodesix common stock at a weighted average price of $0.9242 per share.
- The sales were executed to cover tax obligations arising from the vesting of the RSUs.
- Following these transactions, Pestano directly owns 156,008 shares of Biodesix common stock.
- Pestano also holds 5,513 RSUs vesting quarterly from February 8, 2022, 56,510 RSUs vesting annually from February 8, 2023, and 48,286 RSUs vesting annually from January 15, 2024.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, reflecting routine transactions. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider sales to cover taxes after RSU vesting are a common practice across publicly traded companies.
- The volume of shares sold is relatively small compared to the total outstanding shares of Biodesix, suggesting it's primarily for tax obligations rather than a significant change in investment strategy.
- Comparable companies in the diagnostics industry, such as Exact Sciences or Guardant Health, also see similar Form 4 filings from their executives.
Stakeholder Impact
- The sale of shares by an executive could be perceived negatively by some shareholders, although it's a common practice for covering tax obligations.
- The impact on employees is minimal, as the transaction primarily affects the reporting person's holdings.
Key Dates
| Date | Description |
|---|---|
| 02/08/2022 | Date from which 5,513 RSUs vest in a series of sixteen successive quarterly installments |
| 02/08/2023 | Date from which 56,510 RSUs vest in a series of four successive equal annual installments |
| 01/15/2024 | Date from which 48,286 RSUs vest in a series of four successive equal annual installments |
| 02/10/2025 | Date of RSU exercise |
| 02/11/2025 | Date of common stock sale |
| 02/12/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.